Navigation Links
Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
Date:12/21/2011

ressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the intended effects of the Board's actions, the ability of synthetic DNA-based biologics to optimize the delivery of therapeutic proteins and provide physicians with a way to transform the way diseases are treated, the opportunity for shareholders resulting from our change in priority, the clinical trials that are expected to continue and the Company's intention to seek marketing partners for reaZin™ and wellZin™. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the failure of future clinical trials for our products in the emerging field of synthetic DNA-based therapeutics to be successful, our failure to successfully develop and commercialize products in the emerging field of synthetic DNA-based therapeutics, the failure of our new products to be accepted by physicians, the failure of the new products to have their desired results, our inability to find marketing partners for reaZin™ and wellZin™, the failure of the changes approved by the Board of Directors to have their desired results, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension
2. Adeona Reports Third Quarter 2011 Financial Results
3. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
4. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
5. Adeona Appoints Jeff Lucero Riley as Independent Chairman
6. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
7. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
8. Adeona Appoints George A. Eby to Scientific Advisory Board
9. Adeona Reports Second Quarter 2011 Financial Results
10. Adeona to Host Second Quarter 2011 Investor Conference Call
11. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... & Gamble Company (NYSE: PG ) today announced ... Advisory Panel (SEAP). The new members are: ... Dr. Howard Frumkin – Dean, School of the Public ... Former Secretary, California Environmental Protection Agency ...
... 2011 Following through with plans to expand its Medical ... Florida. Currently operating on a fee for service basis, OMI ... the state. IMD Companies anticipates that OMI will be servicing ... of time. ABOUT IMD COMPANIES, INC. ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3IMD Companies, Inc. Announces OMI Operations in Florida 2
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... 2014 Visual Impact Frequency Training ... been released to the public generating a frenzied ... and fitness community. The commotion surrounding the program's ... Delmonico prompting an investigative review. , "Many gym-goers ... is commonly known as a training 'plateau' where ...
(Date:10/19/2014)... October 19, 2014 The federal ... continuing to move forward in Massachusetts federal court, ... filed over the dialysis medication, Bernstein Liebhard LLP ... October 15th shows 2,127 claims now filed over ... in the U.S. District Court, District of Massachusetts. ...
(Date:10/19/2014)... California (PRWEB) October 19, 2014 Theme and ... plugin for Final Cut Pro X entitled ProSketchy. ... looking text into any video project.” Said Christiana Austin, CEO ... needed to customize their own sketch style text.” , With ... smudged and smeared text all with in Final Cut Pro ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 2Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 3
... , ... ... , ... , , ...
... disease (HD) is a cruel, hereditary condition that leads to ... Currently, there are no treatments to slow down or ... although they do not show symptoms until late in life. ... of Neuroscience , Stephen Ferguson and Fabiola Ribeiro of Robarts ...
... ... supplements has created a brand new market for health supplements, customers who want to ... attention, HGH Supplements like Sytropin. , ... (PRWEB) February 23, 2010 -- Increased positive coverage by respected media ...
... , ... ... ... ...
... ... ... ... ...
... The George Washington University, School of Public Health and Health ... chronic disease, is on the rise in America and released ... surging cost of treatment, and the more than 1 million ... from GW, Changing pO2licy: The Elements for Improving Childhood Asthma ...
Cached Medicine News:Health News:Catholic Health Association Statement on February 25 Health Reform Summit 2Health News:Catholic Health Association Statement on February 25 Health Reform Summit 3Health News:Protecting the brain from a deadly genetic disease 2Health News:Sytropin HGH Shows Promising Anti-Aging Results 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 2Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 3Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 4Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 5Health News:Startling new childhood asthma data 2Health News:Startling new childhood asthma data 3Health News:Startling new childhood asthma data 4
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: